Theoretical modeling of collaterally sensitive drug cycles : shaping heterogeneity to allow adaptive therapy
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
In previous work, we focused on the optimal therapeutic strategy with a pair of drugs which are collaterally sensitive to each other, that is, a situation in which evolution of resistance to one drug induces sensitivity to the other, and vice versa. Yoona (Bull Math Biol 8:1-34,Yoon et al. 2018) Here, we have extended this exploration to the optimal strategy with a collaterally sensitive drug sequence of an arbitrary length, N. To explore this, we have developed a dynamical model of sequential drug therapies with N drugs. In this model, tumor cells are classified as one of N subpopulations represented as [Formula: see text]. Each subpopulation, [Formula: see text], is resistant to '[Formula: see text]' and each subpopulation, [Formula: see text] (or [Formula: see text], if [Formula: see text]), is sensitive to it, so that [Formula: see text] increases under '[Formula: see text]' as it is resistant to it, and after drug-switching, decreases under '[Formula: see text]' as it is sensitive to that drug(s). Similar to our previous work examining optimal therapy with two drugs, we found that there is an initial period of time in which the tumor is 'shaped' into a specific makeup of each subpopulation, at which time all the drugs are equally effective ([Formula: see text]). After this shaping period, all the drugs are quickly switched with duration relative to their efficacy in order to maintain each subpopulation, consistent with the ideas underlying adaptive therapy. West(Canver Res 80(7):578-589Gatenby et al. 2009) and Gatenby (Cancer Res 67(11):4894-4903West et al. 2020). Additionally, we have developed methodologies to administer the optimal regimen under clinical or experimental situations in which no drug parameters and limited information of trackable populations data (all the subpopulations or only total population) are known. The therapy simulation based on these methodologies showed consistency with the theoretical effect of optimal therapy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
---|---|
Enthalten in: |
Journal of mathematical biology - 83(2021), 5 vom: 11. Okt., Seite 47 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yoon, Nara [VerfasserIn] |
---|
Links: |
---|
Themen: |
92-10 Mathematical modeling or simulation for problems pertaining to biology |
---|
Anmerkungen: |
Date Completed 27.10.2021 Date Revised 18.11.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s00285-021-01671-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM331734605 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM331734605 | ||
003 | DE-627 | ||
005 | 20231225214119.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00285-021-01671-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1105.xml |
035 | |a (DE-627)NLM331734605 | ||
035 | |a (NLM)34632539 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yoon, Nara |e verfasserin |4 aut | |
245 | 1 | 0 | |a Theoretical modeling of collaterally sensitive drug cycles |b shaping heterogeneity to allow adaptive therapy |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.10.2021 | ||
500 | |a Date Revised 18.11.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
520 | |a In previous work, we focused on the optimal therapeutic strategy with a pair of drugs which are collaterally sensitive to each other, that is, a situation in which evolution of resistance to one drug induces sensitivity to the other, and vice versa. Yoona (Bull Math Biol 8:1-34,Yoon et al. 2018) Here, we have extended this exploration to the optimal strategy with a collaterally sensitive drug sequence of an arbitrary length, N. To explore this, we have developed a dynamical model of sequential drug therapies with N drugs. In this model, tumor cells are classified as one of N subpopulations represented as [Formula: see text]. Each subpopulation, [Formula: see text], is resistant to '[Formula: see text]' and each subpopulation, [Formula: see text] (or [Formula: see text], if [Formula: see text]), is sensitive to it, so that [Formula: see text] increases under '[Formula: see text]' as it is resistant to it, and after drug-switching, decreases under '[Formula: see text]' as it is sensitive to that drug(s). Similar to our previous work examining optimal therapy with two drugs, we found that there is an initial period of time in which the tumor is 'shaped' into a specific makeup of each subpopulation, at which time all the drugs are equally effective ([Formula: see text]). After this shaping period, all the drugs are quickly switched with duration relative to their efficacy in order to maintain each subpopulation, consistent with the ideas underlying adaptive therapy. West(Canver Res 80(7):578-589Gatenby et al. 2009) and Gatenby (Cancer Res 67(11):4894-4903West et al. 2020). Additionally, we have developed methodologies to administer the optimal regimen under clinical or experimental situations in which no drug parameters and limited information of trackable populations data (all the subpopulations or only total population) are known. The therapy simulation based on these methodologies showed consistency with the theoretical effect of optimal therapy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a 92-10 Mathematical modeling or simulation for problems pertaining to biology | |
650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
700 | 1 | |a Krishnan, Nikhil |e verfasserin |4 aut | |
700 | 1 | |a Scott, Jacob |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of mathematical biology |d 1975 |g 83(2021), 5 vom: 11. Okt., Seite 47 |w (DE-627)NLM000158291 |x 1432-1416 |7 nnns |
773 | 1 | 8 | |g volume:83 |g year:2021 |g number:5 |g day:11 |g month:10 |g pages:47 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00285-021-01671-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 83 |j 2021 |e 5 |b 11 |c 10 |h 47 |